Clinical trials: Infectious Uveitis
Non-infectious Intermediate, Posterior and Panuveitis
Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients
The objective of this study is to evaluate the safety and effectiveness of Humira® (Adalimumab) for the treatment of non-infectious intermediate, posterior, or panuveitis patients under a routine treatment practice.
- Trial name
- NCT03339102
- Where
- 17 sites in South Korea
- Volunteers
- 158 people
- Sponsor
- AbbVie
Active Non-anterior, Non-infectious Uveitis
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIU
The purpose of this study is to find out the efficacy and safety of oral FXS5626 in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).
- Trial name
- NCT07552012
- Testing
- FXS5626 tablet
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Uveitis, Anterior, Panuveitis
A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis
The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious anterior uveitis
- Trial name
- LUMINATE (NCT00404885)
- Testing
- LX211
- Where
- 30 sites in United States, Austria and 5 more
- Volunteers
- 108 people
- Sponsor
- Lux Biosciences, Inc.
Uveitis
Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice
This study aims at evaluating real life effectiveness of originator adalimumab (Humira®) participants with active non-infectious intermediate, posterior and panuveitis (NIIPPU) despite high-dose corticosteroid therapy; including…
- Trial name
- HOPE (NCT03155243)
- Where
- 28 sites in Austria, Colombia and 10 more
- Volunteers
- 155 people
- Sponsor
- AbbVie
Anterior Uveitis
A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anterior Uveitis
This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of non-infectious anterior uveitis.
- Trial name
- NCT00333996
- Testing
- Dexamethasone
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Allergan
Uveitis, Posterior, Uveitis, Intermediate
A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis
The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with clinically quiescent non-infectious uveitis
- Conditions
- Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
- Trial name
- LUMINATE (NCT00404742)
- Testing
- LX211
- Where
- 41 sites in United States, Austria and 5 more
- Volunteers
- 232 people
- Sponsor
- Lux Biosciences, Inc.
Uveitis
Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment
The purpose of this study is to evaluate the efficacy of gevokizumab in reducing the risk of recurrent uveitic disease in subjects with non-infectious uveitis whose disease is currently controlled with systemic treatment.
- Trial name
- EYEGUARD™-C (NCT01747538)
- Testing
- Dose 1 gevokizumab, Dose 2 gevokizumab
- Where
- 115 sites in United States, Argentina and 20 more
- Volunteers
- 281 people
- Sponsor
- XOMA (US) LLC
Non-infectious Uveitis
A 48 Week Study to Evaluate the Efficacy and Safety of Two (2) EYS606 Treatment Regimens in Subjects With Active Chronic Non-infectious Uveitis (CNIU)
The objective of the study is to evaluate the efficacy and safety of two different treatment regimens of EYS606.
- Trial name
- ELECTRO (NCT04207983)
- Testing
- EYS606
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Eyevensys
Non-infectious Anterior Uveitis
Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis
The primary objective of the study is to investigate the safety and tolerability of NOV05 eye drops at two concentrations QID in patients with active non-infectious anterior uveitis.
- Trial name
- EYETAC (NCT07285070)
- Testing
- Tacrolimus ophthalmic solution
- Where
- 6 sites in United States
- Volunteers
- 20 people
- Sponsor
- Novaliq GmbH